Clinical trials: ctDNA, open to volunteers
Advanced Non-small Cell Lung Cancer (NSCLC)
Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).
- Trial name
- INNOVA-LUNG (NCT07649629)
- Testing
- Plasma-based liquid biopsy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Regina Elena Cancer Institute
HER2-positive Early-stage Breast Cancer
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design.
- Trial name
- EUREKA (NCT07402473)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Gastric-Esophageal Cancer
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa…
- Trial name
- SIGNAL GEC-101 (NCT07565857)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 1,000 people
- Sponsor
- Natera, Inc.
Biliary Tract Cancer
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
This prospective, multicenter, observational study aims to evaluate the role of circulating tumor DNA (ctDNA) in advanced or metastatic biliary tract cancer (BTC) patients in Korea.
- Trial name
- NCT07151118
- Testing
- Blood Sampling for ctDNA Analysis
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHA University
Muscle Invasive Upper Tract Urothelial Carcinoma
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual…
- Trial name
- NCT05595408
- Testing
- Adjuvant chemotherapy, adjuvant immunotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- RenJi Hospital
Triple-negative Breast Cancer
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Positive circulating tumor DNA(ctDNA) status is associated with worse prognosis in breast cancer, especially triple-negative breast cancer(TNBC).
- Trial name
- Apollo (NCT04501523)
- Testing
- Tislelizumab, capecitabine
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, HER2-positive Breast Cancer
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
- Trial name
- NCT07459673
- Testing
- Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd)
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer, Rectal Cancer Stage II
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
This is a prospective observational study with three primary objectives: Objective 1: Evaluate the detection rate and changes in circulating tumor DNA (ctDNA) levels in blood samples from colorectal cancer patients before…
- Conditions
- Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT06589388
- Where
- Vietnam
- Volunteers
- 100 people
- Sponsor
- Gene Solutions
Breast Cancer
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA
CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.
- Trial name
- GALIA (NCT07418125)
- Testing
- Liquid biopsy
- Where
- Slovenia
- Volunteers
- 130 people
- Sponsor
- Institute of Oncology Ljubljana
Metastatic Colorectal Cancer ctDNA Surveillance
Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)
Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer…
- Trial name
- NCT07283575
- Testing
- Plasma ctDNA methylation profiling
- Where
- China
- Volunteers
- 497 people
- Sponsor
- Fudan University
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
The goal of this adaptive, interventional study is to assess the efficacy and safety of osimertinib-based adaptive treatment based on ctDNA dynamic monitoring in locally advanced or metastatic EGFRm NSCLC participants with ctDNA…
- Trial name
- NCT07058519
- Testing
- Osimertinib-based adaptive treatment, Osimertinib 80 MG
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Chest Hospital
Breast Cancer
ctDNA Monitoring in Early Breast Cancer
This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.
- Trial name
- NCT04353557
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Lung Cancer
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking.
- Trial name
- NCT05965557
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Lung Cancer, Circulating Tumor DNA
NSCLC Liquid Biopsies and Exhaled VOC
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for…
- Trial name
- NCT06707519
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence, Progression of Bladder Cancer, Transurethral Resection of Bladder Tumor
- Trial name
- NCT07589413
- Testing
- Measurement of Intraoperative Irrigation Fluid Absorption and Perioperative cfDNA Profiling
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhiping Wang
Uterine Cervical Neoplasm
ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer
This study aims to evaluate the clinical feasibility of first-line immunochemotherapy for stage IVB and recurrent cervical cancer guided by circulating tumor DNA (ctDNA), in order to explore the optimal treatment duration or…
- Trial name
- NCT06878196
- Testing
- cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Cancer
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
- Trial name
- NCT06207032
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Tempus AI
Breast Cancer, Digestive Cancer
Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer
Circulating tumor DNA (ctDNA) offers the possibility of accessing the tumor genome from circulating blood through a simple blood test.
- Conditions
- Breast Cancer, Digestive Cancer, Gynecologic Cancer, Circulating Tumor DNA
- Trial name
- NCT04530890
- Testing
- Blood samples
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Poitiers University Hospital
Prostatic Neoplasms, ctDNA
Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy
This study investigates the prognostic value of dynamic changes in Drainage Tumor DNA(dT-DNA) levels found in the peritoneal drainage fluid after radical prostatectomy.
- Trial name
- NCT06707974
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine